The test, one of the first of its kind, is designed to reach patients who may forgo traditional screening because of lack of ...

RHHBY), approved for use with Roche's cobas® HPV test in May 2024. Interested patients can opt for self-collection in clinical settings, such as a doctor's office, or other healthcare settings.

Quest Diagnostics , a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at ...

Both BD's Onclarity test and Roche's cobas test report on 14 strains of HPV. Cervical cancer can be prevented and cured if caught early enough. But the disease remains the fourth most common form ...

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

The self-collection solution, developed in collaboration with Roche and approved for use with Roche’s cobas® HPV test, is designed to provide a discreet and accessible screening option for women, ...

Further improvement in detection capability was achieved from May 2008 with the introduction of real-time PCR (Roche COBAS AmpliPrep/COBAS TaqMan96 real-time PCR assay, Roche Diagnostics, Mannheim, ...